Jeremy Force - Concepedia

Author

Jeremy Force

Also Known As

DiMarco, A.V, J Force, J. Force, Jeremy Force, Jeremy M. Force, Jeremy Meyer Force, Laws, Ewan, Muss, Hyman B., Snyder, J.C

130

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Duke University Duke Medical Center Dana-Farber Cancer Institute University of North Carolina at Chapel Hill Duke Cancer Institute

About

Jeremy Force is an author at Duke University specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	511
2	Immunology	3	3	162
3	Health Sciences	2	2	38
4	Cell Biology	2	2	167
5	Cellular Physiology	1	1	112

Jeremy Force

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor A. Norden-Zfoni, Jayesh Desai, Judith Manola, Clinical Cancer Research	2007	198
The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT) Oluwadamilola M. Fayanju, Yi Ren, Samantha M. Thomas, Annals of Surgery	2018	196
Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity Paul Beaudry, Jeremy Force, George N. Naumov, Clinical Cancer Research	2005	158
Therapeutic Efficacy of Endostatin Exhibits a Biphasic Dose-Response Curve Ilhan Celik, Oǧuzkan Sürücü, Carsten Dietz, Cancer Research	2005	129
Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Gunter Schuch, John V. Heymach, Masashi Nomi, PubMed Endothelial CellsImmunologyCellular PhysiologyTumor BiologyInflammation	2003	112
Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database Cecilia T. Ong, Brittany M. Campbell, Samantha M. Thomas, Annals of Surgical Oncology Surgical OncologyBreast OncologyMedicineCancer RecurrenceCancer Management	2018	112
Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin Geoffrey D. Girnun, Liang Chen, Jessica M. Silvaggi, Clinical Cancer Research	2008	83
Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib Ronan J. Kelly, Arun Rajan, Jeremy Force, Clinical Cancer Research	2011	70
APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses Ashley V. DiMarco, Xiaodi Qin, Brock J. McKinney, Cancer Immunology Research	2021	61
RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence Chao‐Chieh Lin, Nathaniel W. Mabe, Yi-Tzu Lin, Cell Death and Differentiation Breast Cancer RecurrenceOncologyBreast OncologyMedicineBreast Cancer	2020	55

Page 1